{"id":81813,"date":"2026-06-15T12:04:58","date_gmt":"2026-06-15T12:04:58","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/bambusa-therapeutics-presents-positive-preliminary-multiple-ascending-dose-phase-1-data-for-bbt002-at-the-european-academy-of-allergy-clinical-immunology-eaaci-annual-congress-2026\/"},"modified":"2026-06-15T12:04:58","modified_gmt":"2026-06-15T12:04:58","slug":"bambusa-therapeutics-presents-positive-preliminary-multiple-ascending-dose-phase-1-data-for-bbt002-at-the-european-academy-of-allergy-clinical-immunology-eaaci-annual-congress-2026","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/bambusa-therapeutics-presents-positive-preliminary-multiple-ascending-dose-phase-1-data-for-bbt002-at-the-european-academy-of-allergy-clinical-immunology-eaaci-annual-congress-2026\/","title":{"rendered":"Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026"},"content":{"rendered":"
\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

– BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4R\u03b1 and IL-5 – <\/i><\/p>\n

– BBT002 demonstrated rapid, deep, and sustained biomarker effects through at least 8 weeks following multiple doses, consistent with the SAD data, with a ~29.4-day half-life supporting extended dosing intervals –<\/i><\/p>\n

– Topline data from ongoing proof-of-concept trials evaluating BBT002 in patients with COPD and CRSwNP anticipated by year-end 2026 and first half of 2027, respectively –<\/i><\/p>\n

BOSTON<\/span>, June 15, 2026<\/span> \/PRNewswire\/ —\u00a0Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation, long-acting bispecific antibodies for immunology and inflammation, today announced positive preliminary data from the multiple ascending dose (MAD) cohorts of its Phase 1 trial evaluating BBT002 in healthy volunteers. The results were reviewed in an oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place from June 12-15, 2026 in Istanbul, Turkey.<\/p>\n

<\/div>\n

“We are highly encouraged by the preliminary Phase 1 multiple ascending dose data of BBT002 and were pleased to present these results at the EAACI Annual Congress\u2014one of the leading global gatherings of allergy and immunology professionals,” said Thang Ho, Ph.D., Chief Development Officer at Bambusa Therapeutics. “Building on the SAD data we recently shared, the Phase 1 MAD data further support BBT002 as a potentially differentiated, long-acting bispecific antibody targeting IL-4R\u03b1 and IL-5 to address multiple complementary drivers of Type 2 inflammation. BBT002 continues to demonstrate rapid, deep, and sustained biologic activity across multiple clinically relevant biomarkers, including eosinophils, TARC, and pSTAT6, while also supporting the potential for extended dosing intervals through prolonged half-life. We believe these findings reinforce the opportunity for BBT002 to deliver more comprehensive disease control and enhanced dosing convenience for patients with respiratory and other eosinophil-driven inflammatory diseases.”<\/p>\n

The presentation titled “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT002, a Novel Bispecific IL-4R\u03b1\/IL-5 Antibody: Results from the Single- and Multiple-Ascending Dose Portions of a Phase 1 Study of Healthy Volunteers”<\/i> highlighted the following data:<\/p>\n

Percent Change in Eosinophil (EOS) Levels<\/u><\/b>:<\/b> EOS is a clinically established biomarker of Type 2 airway inflammation and IL-5 pathway activity, with elevated levels associated with disease severity and exacerbation risk across multiple respiratory diseases.<\/p>\n